THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE

Objective: Following the launch of the TKI's (tyrosine kinase inhibitors) for the treatment of CML, establishing its significant control over the disease, other dimensions have emerged in regard to the safety of treatment, particularly the effect on Male fertility and fatherhood. This study was...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mohammad Abu-Tineh, Awni Alshurafa, Elrazi Awadelkarim Hamid Ali, Yousef Hailan, Waail Rozi, Abdulqader nashwan, mohamed yassin, Ashraf Omer Elamin Ahmed, Khalid Mohamed Ibrahim Alhaj ALbsheer
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/bbe76b12b82c4a159b160c08c959f90f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bbe76b12b82c4a159b160c08c959f90f
record_format	dspace
spelling	oai:doaj.org-article:bbe76b12b82c4a159b160c08c959f90f2021-11-10T04:32:23ZTHE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE2531-137910.1016/j.htct.2021.10.969https://doaj.org/article/bbe76b12b82c4a159b160c08c959f90f2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011160https://doaj.org/toc/2531-1379Objective: Following the launch of the TKI's (tyrosine kinase inhibitors) for the treatment of CML, establishing its significant control over the disease, other dimensions have emerged in regard to the safety of treatment, particularly the effect on Male fertility and fatherhood. This study was conducted to review the real-life data on the effect of TKI on the fertility of male patients in the National Center of cancer care and research (NCCCR) in Qatar. Case report: Inclusion Criteria: Male patient diagnosed with CML, in Chronic or accelerated phase; 18 years of age or older and actively receiving tyrosine kinase inhibitors including (Imatinib, dasatinib,nilotinib) with the following: -Patients with no known issues with regards to fertility, (fertility is intact) Patients who developed fertility issues after the diagnosis of CML and starting TKI's. has been evaluated by an andrologist, and his evaluation concluded its TKI related. Methodology: A single-center study conducted a mixed-design study by phone interviews with CML male patients in the Chronic or accelerated phase, being followed up in NCCCR (national center for cancer care and research), evaluating the effect of Imatinib, Dasatinib, nilotinib, on their fertility whether they are taking it as first, a second, or third line of treatment. Results: 150 patients were interviewed to be included in the study, 22 patients had concerns related to medications safety and possible transmission of the disease, 33 patients had their families completed by the time of diagnosis. 26 patients have met the inclusion criteria, offspring's total number was 43, 97.6% were full-term, had a normal delivery, and normal average weight at delivery. No stillbirths, fetal demise, or congenital anomaly were reported. All offspring had normal development and growth. Conclusion: Around 98% of male CML patients taking imatinib, Dasatinib, Nilotinib had their offspring born normally with no delivery complications noted, all had no congenital anomaly had normal growth and development, and no CML-related cancers were diagnosed. Further studies with a larger sample size are required to shed light on the TKI outcome on fatherhood in CML patients.Mohammad Abu-TinehAwni AlshurafaElrazi Awadelkarim Hamid AliYousef HailanWaail RoziAbdulqader nashwanmohamed yassinAshraf Omer Elamin AhmedKhalid Mohamed Ibrahim Alhaj ALbsheerElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S15- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Mohammad Abu-Tineh Awni Alshurafa Elrazi Awadelkarim Hamid Ali Yousef Hailan Waail Rozi Abdulqader nashwan mohamed yassin Ashraf Omer Elamin Ahmed Khalid Mohamed Ibrahim Alhaj ALbsheer THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
description	Objective: Following the launch of the TKI's (tyrosine kinase inhibitors) for the treatment of CML, establishing its significant control over the disease, other dimensions have emerged in regard to the safety of treatment, particularly the effect on Male fertility and fatherhood. This study was conducted to review the real-life data on the effect of TKI on the fertility of male patients in the National Center of cancer care and research (NCCCR) in Qatar. Case report: Inclusion Criteria: Male patient diagnosed with CML, in Chronic or accelerated phase; 18 years of age or older and actively receiving tyrosine kinase inhibitors including (Imatinib, dasatinib,nilotinib) with the following: -Patients with no known issues with regards to fertility, (fertility is intact) Patients who developed fertility issues after the diagnosis of CML and starting TKI's. has been evaluated by an andrologist, and his evaluation concluded its TKI related. Methodology: A single-center study conducted a mixed-design study by phone interviews with CML male patients in the Chronic or accelerated phase, being followed up in NCCCR (national center for cancer care and research), evaluating the effect of Imatinib, Dasatinib, nilotinib, on their fertility whether they are taking it as first, a second, or third line of treatment. Results: 150 patients were interviewed to be included in the study, 22 patients had concerns related to medications safety and possible transmission of the disease, 33 patients had their families completed by the time of diagnosis. 26 patients have met the inclusion criteria, offspring's total number was 43, 97.6% were full-term, had a normal delivery, and normal average weight at delivery. No stillbirths, fetal demise, or congenital anomaly were reported. All offspring had normal development and growth. Conclusion: Around 98% of male CML patients taking imatinib, Dasatinib, Nilotinib had their offspring born normally with no delivery complications noted, all had no congenital anomaly had normal growth and development, and no CML-related cancers were diagnosed. Further studies with a larger sample size are required to shed light on the TKI outcome on fatherhood in CML patients.
format	article
author	Mohammad Abu-Tineh Awni Alshurafa Elrazi Awadelkarim Hamid Ali Yousef Hailan Waail Rozi Abdulqader nashwan mohamed yassin Ashraf Omer Elamin Ahmed Khalid Mohamed Ibrahim Alhaj ALbsheer
author_facet	Mohammad Abu-Tineh Awni Alshurafa Elrazi Awadelkarim Hamid Ali Yousef Hailan Waail Rozi Abdulqader nashwan mohamed yassin Ashraf Omer Elamin Ahmed Khalid Mohamed Ibrahim Alhaj ALbsheer
author_sort	Mohammad Abu-Tineh
title	THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
title_short	THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
title_full	THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
title_fullStr	THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
title_full_unstemmed	THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE
title_sort	impact of tyrosine kinase inhibitors on fatherhood in patients with chronic myeloid leukemia, a single institution experience
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/bbe76b12b82c4a159b160c08c959f90f
work_keys_str_mv	AT mohammadabutineh theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT awnialshurafa theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT elraziawadelkarimhamidali theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT yousefhailan theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT waailrozi theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT abdulqadernashwan theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT mohamedyassin theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT ashrafomerelaminahmed theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT khalidmohamedibrahimalhajalbsheer theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT mohammadabutineh impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT awnialshurafa impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT elraziawadelkarimhamidali impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT yousefhailan impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT waailrozi impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT abdulqadernashwan impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT mohamedyassin impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT ashrafomerelaminahmed impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience AT khalidmohamedibrahimalhajalbsheer impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaasingleinstitutionexperience
_version_	1718440687622422528

THE IMPACT OF TYROSINE KINASE INHIBITORS ON FATHERHOOD IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, A SINGLE INSTITUTION EXPERIENCE

Ejemplares similares